Therapy for metastatic melanoma: The past, present, and future

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Metastatic melanoma is the most aggressive form of skin cancer with a median overall survival of less than one year. Advancements in our understanding of how melanoma evades the immune system as well as the recognition that melanoma is a molecularly heterogeneous disease have led to major improvements in the treatment of patients with metastatic melanoma. In 2011, the US Food and Drug Administration (FDA) approved two novel therapies for advanced melanoma: a BRAF inhibitor, vemurafenib, and an immune stimulatory agent, ipilimumab. The success of these agents has injected excitement and hope into patients and clinicians and, while these therapies have their limitations, they will likely provide excellent building blocks for the next generation of therapies. In this review we will discuss the advantages and limitations of the two new approved agents, current clinical trials designed to overcome these limitations, and future clinical trials that we feel hold the most promise.

Original languageEnglish (US)
Article number23
JournalBMC Medicine
Volume10
DOIs
StatePublished - Mar 2 2012

Fingerprint

Melanoma
Clinical Trials
Therapeutics
Skin Neoplasms
United States Food and Drug Administration
Immune System
Survival

Keywords

  • BRAF
  • Ipilimumab
  • Melanoma
  • Therapy
  • Vemurafenib

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapy for metastatic melanoma : The past, present, and future. / Finn, Laura; Markovic, Svetomir Nenad; Joseph, Richard W.

In: BMC Medicine, Vol. 10, 23, 02.03.2012.

Research output: Contribution to journalArticle

@article{b63dffbd97fe46108430b1396c7ee035,
title = "Therapy for metastatic melanoma: The past, present, and future",
abstract = "Metastatic melanoma is the most aggressive form of skin cancer with a median overall survival of less than one year. Advancements in our understanding of how melanoma evades the immune system as well as the recognition that melanoma is a molecularly heterogeneous disease have led to major improvements in the treatment of patients with metastatic melanoma. In 2011, the US Food and Drug Administration (FDA) approved two novel therapies for advanced melanoma: a BRAF inhibitor, vemurafenib, and an immune stimulatory agent, ipilimumab. The success of these agents has injected excitement and hope into patients and clinicians and, while these therapies have their limitations, they will likely provide excellent building blocks for the next generation of therapies. In this review we will discuss the advantages and limitations of the two new approved agents, current clinical trials designed to overcome these limitations, and future clinical trials that we feel hold the most promise.",
keywords = "BRAF, Ipilimumab, Melanoma, Therapy, Vemurafenib",
author = "Laura Finn and Markovic, {Svetomir Nenad} and Joseph, {Richard W}",
year = "2012",
month = "3",
day = "2",
doi = "10.1186/1741-7015-10-23",
language = "English (US)",
volume = "10",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Therapy for metastatic melanoma

T2 - The past, present, and future

AU - Finn, Laura

AU - Markovic, Svetomir Nenad

AU - Joseph, Richard W

PY - 2012/3/2

Y1 - 2012/3/2

N2 - Metastatic melanoma is the most aggressive form of skin cancer with a median overall survival of less than one year. Advancements in our understanding of how melanoma evades the immune system as well as the recognition that melanoma is a molecularly heterogeneous disease have led to major improvements in the treatment of patients with metastatic melanoma. In 2011, the US Food and Drug Administration (FDA) approved two novel therapies for advanced melanoma: a BRAF inhibitor, vemurafenib, and an immune stimulatory agent, ipilimumab. The success of these agents has injected excitement and hope into patients and clinicians and, while these therapies have their limitations, they will likely provide excellent building blocks for the next generation of therapies. In this review we will discuss the advantages and limitations of the two new approved agents, current clinical trials designed to overcome these limitations, and future clinical trials that we feel hold the most promise.

AB - Metastatic melanoma is the most aggressive form of skin cancer with a median overall survival of less than one year. Advancements in our understanding of how melanoma evades the immune system as well as the recognition that melanoma is a molecularly heterogeneous disease have led to major improvements in the treatment of patients with metastatic melanoma. In 2011, the US Food and Drug Administration (FDA) approved two novel therapies for advanced melanoma: a BRAF inhibitor, vemurafenib, and an immune stimulatory agent, ipilimumab. The success of these agents has injected excitement and hope into patients and clinicians and, while these therapies have their limitations, they will likely provide excellent building blocks for the next generation of therapies. In this review we will discuss the advantages and limitations of the two new approved agents, current clinical trials designed to overcome these limitations, and future clinical trials that we feel hold the most promise.

KW - BRAF

KW - Ipilimumab

KW - Melanoma

KW - Therapy

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=84857660324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857660324&partnerID=8YFLogxK

U2 - 10.1186/1741-7015-10-23

DO - 10.1186/1741-7015-10-23

M3 - Article

C2 - 22385436

AN - SCOPUS:84857660324

VL - 10

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

M1 - 23

ER -